Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | BLC2001: Erdafitinib for mUC

Scott Tagawa • 22 May 2020
ASCO 2020
Bladder Cancer Genitourinary Cancer Erdafitinib
BLC2001

Scott Tagawa, MD, MS, FACP, Weill Cornell Medicine, New York, NY, USA, outlines the BLC2001 trial (NCT02365597), which investigated the use of erdafitinib in locally advanced or metastatic urothelial carcinoma (mUC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Scott Tagawa

1:41
PSMAddition: 177Lu-PSMA-617 plus standard of care vs SoC alone in patients with mHSPC
Scott Tagawa • 3 Jun 2023
2:57
Efficacy of sacituzumab govitecan in mUC by Trop-2 expression
Scott Tagawa • 3 Jun 2023
1:51
Future directions in the field of targeted therapies for urothelial carcinoma
Scott Tagawa • 3 Jun 2023
3:07
PSMA-TRT, 225Ac-J591 and 177Lu-PSMA I&T in mCRPC
Scott Tagawa • 3 Jun 2023

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals